Despite impressive revenue growth, the company's forecast growth is lower than the industry, not justifying its high P/S ratio. Many investors remain bullish, unwilling to sell their stock. However, unless conditions improve, the high P/S ratio is seen as unreasonable.
神州细胞-U股票讨论区
暂无评论